Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline
Assessment and Market Forecasts to 2018
Published on September 2011

Report Summary

Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline
Assessment and Market Forecasts to 2018'. The report is an essential source of information and analysis on the global Amyotrophic
Lateral Sclerosis Therapeutics market. The report identifies the key trends shaping and driving the global Amyotrophic Lateral
Sclerosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players
expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable
insights on the pipeline products within the global Amyotrophic Lateral Sclerosis Therapeutics sector. This report is built using data
and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of
industry experts.

Scope

The report provides information on the key drivers and challenges of the Amyotrophic Lateral Sclerosis Therapeutics market. Its
scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Amyotrophic Lateral Sclerosis Therapeutics
market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by
seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Amyotrophic Lateral Sclerosis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a
qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the
Amyotrophic Lateral Sclerosis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Amyotrophic Lateral Sclerosis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by
identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Amyotrophic Lateral Sclerosis Therapeutics
market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to
impact the global Amyotrophic Lateral Sclerosis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of
various competitors.

Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 1/8


- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive
advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities
for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Amyotrophic Lateral Sclerosis Therapeutics market landscape' ' Identify, understand and
capitalize.

Table of Content

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Amyotrophic Lateral Sclerosis Therapeutics: Introduction 7
2.1 Overview 7
2.2 Epidemiology 8
2.3 Etiology and Pathophysiology 10
2.4 Symptoms 10
2.5 Diagnosis 11
2.6 Treatment and Management Pattern 12
2.7 Referral Pathway 16
2.8 GlobalData Pipeline Report Guidance 17
3 Amyotrophic Lateral Sclerosis Therapeutics: Market Characterization 18
3.1 Amyotrophic Lateral Sclerosis Therapeutics Market Size (2005 - 2010) - Global 18
3.2 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018) - Global 19
3.3 Amyotrophic Lateral Sclerosis Therapeutics Market Size (2005 - 2010): The US 20
3.4 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010-2018): The US 21
3.5 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): France 22
3.6 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): France 23
3.7 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): Germany 24
3.8 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): Germany 25
3.9 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): Italy 26
3.10 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): Italy 27
3.11 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): Spain 28
3.12 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): Spain 29
3.13 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): The UK 30
3.14 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): The UK 31
3.15 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): Japan 32
3.16 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): Japan 33
3.17 Drivers and Barriers for the Amyotrophic Lateral Sclerosis Therapeutics Market 34
3.17.1 Drivers for the Amyotrophic Lateral Sclerosis Therapeutics Market 34
3.17.2 Barriers for the Amyotrophic Lateral Sclerosis Therapeutics Market 34
3.18 Opportunity and Unmet Need Analysis 35
3.19 Key Takeaway 36
4 Amyotrophic Lateral Sclerosis Therapeutics: Competitive Assessment 37
4.1 Overview 37



4.2 Strategic Competitor Assessment 37
4.3 Product Profile for the Major Marketed Products in the Amyotrophic Lateral Sclerosis Therapeutics Market 38
4.3.1 Rilutek (riluzole) 38
5 Amyotrophic Lateral Sclerosis Therapeutics: Pipeline Assessment 40
5.1 Overview 40
5.2 Strategic Pipeline Assessment 40
5.3 Amyotrophic Lateral Sclerosis Therapeutics Pipeline ' Pipeline by Phases of Development 40
5.3.1 Amyotrophic Lateral Sclerosis Therapeutics ' Phase III Pipeline 41
5.3.2 Amyotrophic Lateral Sclerosis Therapeutics ' Phase II Pipeline 41
5.3.3 Amyotrophic Lateral Sclerosis Therapeutics ' Phase I Pipeline 42
5.3.4 Amyotrophic Lateral Sclerosis Therapeutics ' Preclinical Pipeline 42
5.3.5 Amyotrophic Lateral Sclerosis Therapeutics ' Discovery Pipeline 43
5.3.6 Amyotrophic Lateral Sclerosis Therapeutics ' Phase Unknown 43
5.4 Amyotrophic Lateral Sclerosis Therapeutics Market ' Pipeline by Mechanism of Action 44
5.5 Technology Trends Analytical Framework 45
5.6 ALS Therapeutics ' Most Promising Drugs Under Development 46
5.7 Molecule Profile for Promising Drugs under Development 47
5.7.1 Dexpramipexole (KNS-760704) 47
5.7.2 Olesoxime (TRO 19622) 49
5.7.3 Radicut 50
5.7.4 ALS-02 51
5.8 Profile for Other Drugs under Clinical Development 52
5.8.1 E0302 (mecobalamin) 52
6 Amyotrophic Lateral Sclerosis Therapeutics: Clinical Trials Mapping 53
6.1 Clinical Trials by Country (US, EU5 & Japan) 53
6.2 Clinical Trials by Phase 54
6.3 Clinical Trials by Trial Status 55
6.4 Prominent Sponsors 56
6.5 Key Companies Participating in Therapeutics Clinical Trials 58
7 Amyotrophic Lateral Sclerosis Therapeutics: Stategic Assessment 59
7.1 Key Events Impacting on the Future Market 59
7.2 Amyotrophic Lateral Sclerosis Therapeutics: Implications for Future Market Competition 59
8 Amyotrophic Lateral Sclerosis Therapeutics: Future Players 61
8.1 Introduction 61
8.2 Company Profiles 62
8.2.1 The Avicena Group Inc. 62
8.2.2 Biogen Idec/Knopp Bioscience Inc. 62
8.2.3 Actelion Pharmaceuticals Ltd. 64
8.2.4 Mitsubishi Tanabe Pharma Corporation 64
8.2.5 Eisai Co. Ltd 65
8.2.6 Other Companies in the Amyotrophic Lateral Sclerosis Therapeutics Market 67
9 Amyotrophic Lateral Sclerosis Therapeutics: Licensing and Partnership Deals 72
10 Amyotrophic Lateral Sclerosis Therapeutics: Appendix 74
10.1 Market Definitions 74
10.2 Abbreviations 74
10.3 Methodology 75
10.3.1 Coverage 76
10.3.2 Secondary Research 76



10.3.3 Forecasting 76
10.3.4 Primary Research 78
10.3.5 Expert Panel Validation 78
10.4 Contact Us 78
10.5 Disclaimer 78
10.6 Bibliography 79

List of Tables

Table 1: Incidence of ALS in Top Seven Countries and the World 9
Table 2: EI Escorial Criteria for Diagnosing ALS 11
Table 3: Drugs for the Symptomatic Treatment of ALS 12
Table 4: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Revenue($m), 2005-2010 18
Table 5: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Forecast($m), 2010-2018 20
Table 6: Amyotrophic Lateral Sclerosis Therapeutics Market, The US, Revenue($m), 2005-2010 20
Table 7: Amyotrophic Lateral Sclerosis Therapeutics Market, The US, Forecast($m), 2010-2018 21
Table 8: Amyotrophic Lateral Sclerosis Therapeutics Market, France, Revenue($m), 2005-2010 22
Table 9: Amyotrophic Lateral Sclerosis Therapeutics Market, France, Forecast($m), 2010-2018 23
Table 10: Amyotrophic Lateral Sclerosis Therapeutics Market, Germany, Revenue($m), 2005-2010 24
Table 11: Amyotrophic Lateral Sclerosis Therapeutics Market, Germany, Forecast ($m), 2010-2018 25
Table 12: Amyotrophic Lateral Sclerosis Therapeutics Market, Italy, Revenue ($m), 2005-2010 26
Table 13: Amyotrophic Lateral Sclerosis Therapeutics Market, Italy, Forecast ($m), 2010-2018 27
Table 14: Amyotrophic Lateral Sclerosis Therapeutics Market, Spain, Revenue ($m), 2005-2010 28
Table 15: Amyotrophic Lateral Sclerosis Therapeutics Market, Spain, Forecast ($m), 2010-2018 29
Table 16: Amyotrophic Lateral Sclerosis Therapeutics Market, UK, Revenue ($m), 2005-2010 30
Table 17: Amyotrophic Lateral Sclerosis Therapeutics Market, UK, Forecast ($m), 2010-2018 31
Table 18: Amyotrophic Lateral Sclerosis Therapeutics Market, Japan, Revenue ($m), 2005-2010 32
Table 19: Amyotrophic Lateral Sclerosis Therapeutics Market, Japan, Forecast ($m), 2010-2018 33
Table 20: Amyotrophic Lateral Sclerosis Therapeutics ' Phase III Clinical Pipeline, 2011 41
Table 21: Amyotrophic Lateral Sclerosis Therapeutics ' Phase II Clinical Pipeline, 2011 41
Table 22: Amyotrophic Lateral Sclerosis Therapeutics ' Phase l Pipeline, 2011 42
Table 23: Amyotrophic Lateral Sclerosis Therapeutics ' Preclinical Pipeline, 2011 42
Table 24: Amyotrophic Lateral Sclerosis Therapeutics ' Discovery Pipeline, 2011 43
Table 25: Amyotrophic Lateral Sclerosis Therapeutics ' Phase Unknown, 2011 43
Table 26:Amyotrophic Lateral Sclerosis Therapeutics ' Most Promising Drugs Under Development, 2011 46
Table 27: A Brief History of dexpramipexole 47
Table 28: A Brief History of olesoxime 49
Table 29: Amyotrophic Lateral Sclerosis Therapeutics, Clinical Trials by Country,2011 53
Table 30: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase of Development, 2011 54
Table 31: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2011 55
Table 32: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 56
Table 33: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 57
Table 34: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Top Companies, 2011 58
Table 35: The Avicena Group Inc. - CNS Pipeline Portfolio, 2011 62
Table 36: Biogen Idec. ' CNS Pipeline Portfolio, 2011 63
Table 37: Knopp Bioscience Inc. ' CNS Pipeline Portfolio, 2011 63
Table 38: Actelion Pharmaceuticals Ltd - CNS Pipeline Portfolio, 2011 64
Table 39: Mitsubishi Tanabe Pharma Corporation ' CNS Pipeline Portfolio, 2011 65



Table 40: Eisai Co. Ltd. ' CNS Pipeline Portfolio, 2011 66
Table 41: Other Companies in the Pipeline, 2011 67
Table 42: Licensing and Partnership Deals, 2010-2011 72

List of Figures

Figure 1: Normal and ALS-Affected Nerve Cells 7
Figure 2: Normal and ALS affected Motor Neurons/Muscles 8
Figure 3: Management Algorithm for Sialorrhea in Patients with ALS 13
Figure 4: Management Algorithm for Nutrition Deficiency in Patients with ALS 14
Figure 5: Management Algorithm for Respiratory Problems in Patients with ALS 15
Figure 6: Amyotrophic Lateral Sclerosis Therapeutics, Referral Pathway 16
Figure 7: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Revenue($m), 2005-2010 18
Figure 8: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Forecast ($m), 2010-2018 19
Figure 9: Amyotrophic Lateral Sclerosis Therapeutics Market, The US, Revenue($m), 2005-2010 20
Figure 10: Amyotrophic Lateral Sclerosis Therapeutics Market, The US, Forecast($m), 2010-2018 21
Figure 11: Amyotrophic Lateral Sclerosis Therapeutics Market, France, Revenue($m), 2005-2010 22
Figure 12: Amyotrophic Lateral Sclerosis Therapeutics Market, France, Forecast($m), 2010-2018 23
Figure 13: Amyotrophic Lateral Sclerosis Therapeutics Market, Germany, Revenue($m), 2005-2010 24
Figure 14: Amyotrophic Lateral Sclerosis Therapeutics Market, Germany, Forecast ($m), 2010-2018 25
Figure 15: Amyotrophic Lateral Sclerosis Therapeutics Market, Italy, Revenue ($m), 2005-2010 26
Figure 16: Amyotrophic Lateral Sclerosis Therapeutics Market, Italy, Forecast ($m), 2010-2018 27
Figure 17: Amyotrophic Lateral Sclerosis Therapeutics Market, Spain, Revenue ($m), 2005-2010 28
Figure 18: Amyotrophic Lateral Sclerosis Therapeutics Market, Spain, Forecast ($m), 2010-2018 29
Figure 19: Amyotrophic Lateral Sclerosis Therapeutics Market, UK, Revenue ($m), 2005-2010 30
Figure 20: Amyotrophic Lateral Sclerosis Therapeutics Market, UK, Forecast ($m), 2010-2018 31
Figure 21: Amyotrophic Lateral Sclerosis Therapeutics Market, Japan, Revenue ($m), 2005-2010 32
Figure 22: Amyotrophic Lateral Sclerosis Therapeutics Market, Japan, Forecast ($m), 2010-2018 33
Figure 23: Opportunity and Unmet Need in the Amyotrophic Lateral Sclerosis Therapeutics Market, 2010 35
Figure 24: Strategic Competitor Assessment of the Major Marketed Products for Amyotrophic Lateral Sclerosis, 2011 37
Figure 25: Amyotrophic Lateral Sclerosis Therapeutics, Molecular Structure of Rilutek 38
Figure 26: Amyotrophic Lateral Sclerosis Therapeutics, Pipeline by Phase of Development, 2011 40
Figure 27: Amyotrophic Lateral Sclerosis Therapeutics Market ' Pipeline by Mechanism of Action, 2011 44
Figure 28: Technology Trends Analytic Framework of the Amyotrophic Lateral Sclerosis Therapeutics Pipeline, 2011 45
Figure 29: Technology Trends Analytic Framework of the Amyotrophic Lateral Sclerosis Therapeutics Pipeline - Description, 2011 46
Figure 30: Amyotrophic Lateral Sclerosis Therapeutics, Molecular Structure of dexpramipexole 47
Figure 31: Amyotrophic Lateral Sclerosis Therapeutics, Molecular Structure of olesoxime 49
Figure 32: Amyotrophic Lateral Sclerosis Therapeutics - Clinical Trials by Country, 2011 53
Figure 33: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase of Development, 2011 54
Figure 34: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2011 55
Figure 35: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 56
Figure 36: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 57
Figure 37: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Top Companies, 2011 58
Figure 38: Amyotrophic Lateral Sclerosis Therapeutics Market, Drivers and Barriers, 2011 59
Figure 39: Implications for Future Market Competition in the Amyotrophic Lateral Sclerosis Therapeutics Market, 2011 59
Figure 40: Amyotrophic Lateral Sclerosis Therapeutics ' Clinical Pipeline by Company, 2011 61

Companies Mentioned



The Avicena Group Inc.
Biogen Idec/Knopp Bioscience Inc.
Actelion Pharmaceuticals Ltd.
Mitsubishi Tanabe Pharma Corporation
Eisai Co. Ltd


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 3 500.00 Quantity: _____

Site License--USD 7 000.00 Quantity: _____

Corporate License--USD 10 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018